Abstract
Hepatotoxicity is a common clinical manifestation associated with a wide range of anticancer therapies. Because of the inherent toxicity of anticancer therapies, oncologists must maintain a broad understanding of their effects on the body, including the liver. Therefore, the study was conducted to examine the effects of two doses of L-carnitine on damaged liver as a result of giving cytarabine. Twenty-four male rats were used in the experiment. The rats divided to four group each group with six rats,the first group injected normal saline intraperitoneally and set as control group(G1), the second group injected cytarabine 25 mg/kg/bw, intraperitoneally and set as (G2), the third group injected cytarabine 25 mg/kg/bw and 50 mg/kg/bw, L-carnitine intraperitoneally and set as (G3), the fourth group injected cytarabine 25 mg/kg/bw and 300 mg/kg/bw, L-carnitine intraperitoneally and set as (G4), the study showed that use of L-carnitine reduced the harmful effect of cytarabine in the body when compared to other groups that were injected only with cytarabine at level of (p-value <0.05).The rats treated with L-carnitine have shown significant elevation in CAT and SOD and reduction of the level of MDA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
